FDA Says Retatrutide Is a Drug, Not a Biologic—Again
Wize Peptides | Source check: October 14, 2026
Eli Lilly wants retatrutide classified as a biologic. The FDA has again rejected that request.
In a decision dated October 2, 2026, and filed in court October 8, the agency said retatrutide belongs on the drug approval pathway, not the biologic pathway. CourtListener
Wize Summary: This is about which FDA rules apply. It does not approve retatrutide, mean the FDA decided it does not work, or make compounding legal. CourtListener
Why has the FDA said no twice?
FDA first classified retatrutide as a drug in March 2024. Lilly challenged that decision in court. CourtListener
In 2025, a federal district court agreed that retatrutide did not meet FDA's definition of a protein. But the judge found a problem with FDA's explanation of why it also failed to qualify as an "analogous product"—something similar to a protein.
The court sent that question back to FDA for another look. It did not order FDA to classify retatrutide as a biologic. GovInfo
The October decision is FDA's answer after that review. CourtListener
Why does retatrutide's amino acid count matter?
For the protein category being disputed, FDA's rule requires more than 40 alpha amino acids in a specific, defined sequence. "Alpha" identifies a particular type of amino acid. The rule does not simply count every attached building block. GovInfo
Retatrutide's main chain contains 39 alpha amino acids. Lilly argues that two attached components should bring the count to 41. FDA says those attachments do not make retatrutide meet the protein rule. GovInfo
FDA also rejected Lilly's backup argument that retatrutide should qualify as an analogous product to a protein. Under its new explanation, FDA says retatrutide still lacks the required features. CourtListener
In plain English: the disagreement is about which building blocks count—not just the number on the page.
Why does drug vs. biologic classification matter?
The classification can affect how future competing products reach the market. Here, "drug versus biologic" refers to the legal approval route. Biologics are medicines too. U.S. Food and Drug Administration
Future generic or biosimilar versions
If retatrutide remains on the drug pathway, future manufacturers could seek generic approval if they meet FDA's requirements.
If it is classified and approved as a biologic, follow-on versions would generally use the biosimilar pathway instead. A biosimilar is highly similar to an approved biologic, with no clinically meaningful differences.
Both routes require FDA review. Neither gives another company permission to start selling a copy automatically. U.S. Food and Drug Administration
Protection from certain competitors
A qualifying new biologic generally receives 12 years of protection from FDA approval of a biosimilar based on it. A qualifying new chemical drug generally receives five years of new-chemical-entity exclusivity.
These are different legal protections—not guaranteed dates when cheaper versions arrive. Patents and other requirements can still affect the timing. GovInfo
Possible future compounding
Sections 503A and 503B are federal provisions that let certain compounded drugs qualify for exemptions from normal FDA approval requirements. Strict conditions apply.
Biologics do not qualify for those exemptions. Keeping retatrutide on the drug pathway could leave those provisions relevant in the future—but would not automatically make it eligible for compounding. U.S. Food and Drug Administration
Can retatrutide be compounded today?
No. FDA currently states that retatrutide cannot be used in compounding under federal law. It is not a component of an FDA-approved drug, and FDA has not found it safe and effective for any condition.
Drug classification is not a compounding green light. U.S. Food and Drug Administration
What happens next in Lilly's appeal?
The Seventh Circuit heard oral arguments on September 24, 2026. The immediate dispute now includes whether that court can hear Lilly's existing appeal. Seventh Circuit Court of Appeals
The government's position: Lilly should challenge FDA's new decision in district court first, before bringing a later appeal. DOJ acknowledges that Seventh Circuit precedent supports immediate appeals in this setting, but argues that approach is wrong. CourtListener
Lilly's position: The appeal should proceed now. Lilly argues that FDA's completed review strengthens the case for the appeals court to hear the dispute without further delay. CourtListener
Status checked October 14, 2026: No final Seventh Circuit ruling was found in the public sources reviewed for this article. The October 8 filings are arguments from the parties—not a new ruling by the judges. CourtListener
The Wize take
The FDA has rejected Lilly's requested biologic classification again. That is not the same as rejecting retatrutide as a future treatment—and it does not authorize compounding today. CourtListener
The longer-term issue is how competition and possible compounding would be handled if retatrutide eventually reaches the market. For now, keep three separate questions separate: classification, approval, and compounding. U.S. Food and Drug Administration
This article is for education and news reporting, not medical or legal advice.
Related guides.
Guidesmg vs mcg vs mL: How to Read a Peptide Dose Correctly
What mg, mcg, mL and U-100 units each measure, why the same syringe number means a different amount in a different vial, and how to check a calculation before you measure.
CommentaryI'm calling it now: the peptide conversation is moving to X
Platform rules, a compounding proposal and a private certification company are quietly deciding which peptide voices get promoted. Here is what to watch.
GuidesGLP-1 Weight Regain: What the Tirzepatide Trials Show
What SURMOUNT-4 and SURMOUNT-MAINTAIN actually measured about weight regain after tirzepatide, and why "microdosing" is not the same as a lower approved maintenance dose.
NewsGLP-1s Linked to Fewer Psychiatric Hospital Visits in People With Schizophrenia and Diabetes
People who started a GLP-1 medication had a lower hazard of psychiatric hospitalization and emergency visits than the comparison groups. Here's what the study can and cannot tell us.
NewsTepeptide Buyers Want Answers After Nearly $16,000 Order Reportedly Fails Testing at Two Labs
A buyer group says it spent nearly $16,000 on 127 Tepeptide kits that reportedly failed identity testing at two labs, and that the seller then stopped responding.
Get a new guide every week.
Subscribe free and the Beginner's Guide to Peptide Research is yours instantly.